DK345889A - Anvendelse af 5-ht-3-receptorantagonist - Google Patents

Anvendelse af 5-ht-3-receptorantagonist Download PDF

Info

Publication number
DK345889A
DK345889A DK345889A DK345889A DK345889A DK 345889 A DK345889 A DK 345889A DK 345889 A DK345889 A DK 345889A DK 345889 A DK345889 A DK 345889A DK 345889 A DK345889 A DK 345889A
Authority
DK
Denmark
Prior art keywords
pct
receptor antagonist
sec
treatment
date
Prior art date
Application number
DK345889A
Other languages
English (en)
Other versions
DK345889D0 (da
Inventor
Andrew James Williams
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878726717A external-priority patent/GB8726717D0/en
Priority claimed from GB878726716A external-priority patent/GB8726716D0/en
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of DK345889D0 publication Critical patent/DK345889D0/da
Publication of DK345889A publication Critical patent/DK345889A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrotherapy Devices (AREA)
  • Conductive Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
DK345889A 1987-11-14 1989-07-12 Anvendelse af 5-ht-3-receptorantagonist DK345889A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878726717A GB8726717D0 (en) 1987-11-14 1987-11-14 Treatment
GB878726716A GB8726716D0 (en) 1987-11-14 1987-11-14 Treatment
PCT/GB1988/000994 WO1989004660A1 (en) 1987-11-14 1988-11-14 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction

Publications (2)

Publication Number Publication Date
DK345889D0 DK345889D0 (da) 1989-07-12
DK345889A true DK345889A (da) 1989-07-12

Family

ID=26293045

Family Applications (1)

Application Number Title Priority Date Filing Date
DK345889A DK345889A (da) 1987-11-14 1989-07-12 Anvendelse af 5-ht-3-receptorantagonist

Country Status (9)

Country Link
US (1) US5098909A (da)
EP (1) EP0340270B1 (da)
JP (1) JPH02502185A (da)
KR (1) KR890701099A (da)
AT (1) ATE78162T1 (da)
AU (1) AU616706B2 (da)
DE (1) DE3872872T2 (da)
DK (1) DK345889A (da)
WO (1) WO1989004660A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
WO2000051582A2 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
GB9918425D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
WO2001095903A1 (en) * 2000-06-15 2001-12-20 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
AU2003276919B2 (en) * 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2004091606A1 (en) * 2003-04-16 2004-10-28 Orchid Chemicals & Pharmaceuticals, Ltd. Treatment of bronchial asthma using 5-ht3 receptor antagonists
DE602004010299T2 (de) * 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
JP2007534692A (ja) * 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
JP2007538011A (ja) * 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
BRPI0517494A (pt) * 2004-12-22 2008-10-14 Memory Pharm Corp composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure

Also Published As

Publication number Publication date
JPH02502185A (ja) 1990-07-19
KR890701099A (ko) 1989-12-19
DK345889D0 (da) 1989-07-12
AU616706B2 (en) 1991-11-07
DE3872872T2 (de) 1993-02-04
WO1989004660A1 (en) 1989-06-01
US5098909A (en) 1992-03-24
AU2626488A (en) 1989-06-14
EP0340270A1 (en) 1989-11-08
EP0340270B1 (en) 1992-07-15
DE3872872D1 (de) 1992-08-20
ATE78162T1 (de) 1992-08-15

Similar Documents

Publication Publication Date Title
DK345889D0 (da) Anvendelse af 5-ht-3-receptorantagonist
NO2015027I1 (no) Mepolizumab
BR9506305A (pt) Aparelho e processo para preparação de formas sólidas com desprendimento controlado do ingrediente ativo
DK0804196T3 (da) Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
DK0506853T3 (da) Anvendelse af GABA-B selektive agonister som antitussive midler
IT1196645B (it) Apparecchio per l'2nfilamento e losfilamento automatico di tubolari,come calze e calzamaglie,in apparecchi di ispezione
IT8367542A0 (it) Bocchettone di scarico per apparecchi igienico sanitari e simili
IT1179444B (it) Composizione farmaceutica a base di estratto solubile in piridina e di endotossina detossicata raffinata e suo impiego
DK0482089T3 (da) Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
FI880954A7 (fi) Seos ja menetelmä immunologista kastrointia varten.
ES545155A0 (es) Procedimiento para la obtencion de (pirrol-1-il)-fenil-dihi-dropiridazinona
ES2057910T3 (es) Procedimiento y dispositivo para la obtencion de caseina beta.
ATE127021T1 (de) Immunstimulierendes arzneimittel, das polare glycopeptidolipide von mycobakterium-chelonae enthält.
FI925944A0 (fi) Arylalkylestrar av 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-antracenkarboxylsyra med terapeutisk effekt
DK149590C (da) Analogifremgangsmaade til fremstilling af 2-aryl-3,4-diaza-bicyclo(4,1,0)hepten-(2)-on-(5)-forbindelser
ES2034678T3 (es) Procedimiento para aumentar la productividad de los cerdos.
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
NO874241D0 (no) Terapeutisk aktive salter.
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
NO885615D0 (no) Innretning for utsendelse av insektbekjempende og luktfjernende midler.
PT94619A (pt) Metodo para o tratamento de texteis utilizando compostos de silicio com grupos funcionais dioxolano
IT216577Z2 (it) Attrezzatura igienico sanitaria particolarmente studiata per bagni e simili.
MX19738A (es) Antagonistas de 5-ht3 oxagranatan y procedimiento para su preparacion.
IT8230676V0 (it) Chiave (utensile) universale per pilette di vasche, lavabi e simili.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment